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AbsTrACT
Objective To investigate the variation in severe 
neonatal morbidity among very preterm (VPT) infants 
across European regions and whether morbidity rates are 
higher in regions with low compared with high mortality 
rates.
Design Area-based cohort study of all births before 32 
weeks of gestational age.
setting 16 regions in 11 European countries in 
2011/2012.
Patients Survivors to discharge from neonatal care 
(n=6422).
Main outcome measures Severe neonatal morbidity 
was defined as intraventricular haemorrhage grades 
III and IV, cystic periventricular leukomalacia, surgical 
necrotizing enterocolitis and retinopathy of prematurity 
grades ≥3. A secondary outcome included severe 
bronchopulmonary dysplasia (BPD), data available in 14 
regions. Common definitions for neonatal morbidities 
were established before data abstraction from medical 
records. Regional severe neonatal morbidity rates were 
correlated with regional in-hospital mortality rates for 
live births after adjustment on maternal and neonatal 
characteristics.
results 10.6% of survivors had a severe neonatal 
morbidity without severe BPD (regional range 6.4%–
23.5%) and 13.8% including severe BPD (regional 
range 10.0%–23.5%). Adjusted inhospital mortality 
was 13.7% (regional range 8.4%–18.8%). Differences 
between regions remained significant after consideration 
of maternal and neonatal characteristics (P<0.001) and 
severe neonatal morbidity rates were not correlated with 
mortality rates (P=0.50).
Conclusion Severe neonatal morbidity rates for VPT 
survivors varied widely across European regions and 
were independent of mortality rates.
InTrODuCTIOn
Delivery before 32 weeks of gestation occurs 
in 1%–2% of births, contributing to significant 
mortality and morbidity.1 Advances in obstetric and 
neonatal care with more active management of these 
infants2 have increased survival in high-income 
countries.3–7 However, differences in mortality 
rates persist between and within countries,6 which 
may be partly explained by professional attitudes 
and decision-making regarding extremely preterm 
infants.6 Differences in maternal demographic and 
socioeconomic characteristics and the organisation 
and quality of obstetrical and neonatal care also 
contribute to mortality variations.8 9
Increased survival among very preterm infants 
may lead to higher risks of neonatal morbidity 
among survivors.10 11 Studies in the 1990s and 
2000 provided conflicting reports; some found 
increasing neonatal morbidity as survival improved, 
while others reported no change.12 More recent 
studies show that improved survival did not result 
in increased rates of major neonatal morbidities, 
although rates of bronchopulmonary dysplasia 
(BPD) may increase as more extremely preterm 
infants survive.13–18
While repeated studies by the same research 
groups enable standardised methodologies and 
comparable results over time,13–15 comparing 
morbidity across settings is more challenging, as 
morbidity has been measured using multiple defi-
nitions and study populations. Consequently, in 
contrast to mortality, few comparable data exist 
concerning geographical variation in morbidity in 
very preterm populations.19 20 Quantifying trade-
offs between mortality and morbidity is relevant 
in a cross-country context, as improved neonatal 
What is already known on this topic?
 ► Mortality rates for very preterm infants differ 
across European regions.
 ► Morbidity rates may vary, but cross-
regional comparisons are difficult because 
of unstandardised definitions and patient 
populations.
 ► Mortality rates could affect the prevalence of 
severe neonatal morbidity among survivors 
if selection due to mortality affects patient 
case mix.
What this study adds?
 ► This study confirms wide variations in neonatal 
morbidity across European regions using 
common definitions and patient populations.
 ► Adjusting for maternal and neonatal 
characteristics reduces the variation between 
regions, but does not explain it.
 ► A trade-off between mortality and morbidity 
rates at the regional level is not observed.
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Table 1 Characteristics of live births and survivors to discharge 
from the neonatal unit
Characteristics
Live births
(n = 7438) 
survivors to 
discharge (n = 6422) 
Infant characteristics Mean (SD) Mean (SD)
  Gestational age 28.4 (2.4) 28.9 (2.0)
  Birth weight, mean 1194 (402) 1255 (370)
Gestational age % %
  <25 weeks 9.2 3.7
  25–27 weeks 23.0 21.1
  28–29 weeks 24.9 26.9
  30–31 weeks 42.9 48.3
Male 54.3 53.9
Multiple pregnancy 31.2 31.7
SGA*
  <3rd percentile 20.2 20.2
  3–<10th percentile 11.4 11.7
  ≥10th percentile 68.4 68.1
Apgar score at 5 min
  <4 6.6 2.5
  4–6 13.6 12.4
  ≥7 79.9 85.1
Congenital anomaly† 7.1 7.3
Maternal and pregnancy characteristics
Maternal age
  <35 years 73.9 73.6
  35 years 26.1 26.4
Parity
  Nulliparous 56.2 56.8
  Multiparous 43.8 43.2
PPROM 25.1 25.0
Pre-eclampsia/eclampsia/HELLP 14.9 15.7
Healthcare and management
Any antenatal steroids 86.3 89.2
Delivery in level III unit 77.9 78.0
Neonatal transport 11.3 11.0
Type of delivery
  Prelabour caesarean 39.9 41.8
  Intrapartum caesarean 24.9 25.9
  Vaginal delivery 35.2 32.4
Initial respiratory management
  None 15.4 12.4
  nCPAP 41.4 46.3
  Mechanical ventilation 43.2 41.2
*Small for gestational age using intrauterine references.
†Congenital anomalies reportable to Eurocat, but not severe. Cases with severe 
anomalies were excluded.
HELLP, hemolysis  elevated  liver enzymes low  platelet count; PPROM,  preterm 
premature rupture of membrane.
survival may result in higher rates of impairment. Even if 
morbidity rates do not increase, the number of surviving high-
risk infants will be greater when mortality is lower. This informa-
tion is important for planning for health, social and educational 
services.
Using a contemporary prospective, population-based, multi-
regional cohort of live births <32 weeks gestation, we aimed to 
describe the variation in severe neonatal morbidity in Europe 
using standardised definitions, and to assess the potential trade-
offs between survival and subsequent morbidity.
MeTHODs
study design
The ‘Effective Perinatal Intensive Care In Europe’ (EPICE) cohort 
is a prospective study of all stillbirths and live births between 
22+0 and 31+6 weeks gestation in 19 regions in 11 European 
countries that together have >850 000 births annually: Belgium 
(Flanders), Denmark (Eastern Region), Estonia (entire country), 
France (Burgundy, Ile-de-France and the Northern region), 
Germany (Hesse and Saarland), Italy (Emilia-Romagna, Lazio 
and Marche), the Netherlands (Central and Eastern region), 
Poland (Wielkopolska), Portugal (Lisbon and Northern region), 
Sweden (greater Stockholm area) and the UK (East Midlands, 
Northern, and Yorkshire and Humber regions).21 The regions 
were included because of their geographical and organisational 
diversity, their ability to implement the study protocol and 
sample size considerations. Data were collected on births over 
varying 12-month periods between April 2011 and September 
2012, except in French regions (6-month study period).
Data were extracted from medical records in obstetric and 
neonatal units using standardised pretested forms. Gestational age 
(GA) was defined as the best obstetric assessment based on infor-
mation on last menstrual period and antenatal ultrasounds, which 
are part of routine obstetric care in all regions. The completeness 
of inclusions was cross-checked against delivery unit registers or 
routine regional statistics. Infants were followed until discharge 
from hospital to home or into long-term care, or death.
study population
Three of the regions, Saarland (Germany), Marche (Italy) and 
Burgundy (France), were excluded because they had fewer than 
100 eligible infants and therefore the number of severe morbid 
events was low. These regions had mortality and morbidity rates 
similar to the cohort average. For the analysis of mortality, we 
included 7438 live births after exclusion of stillbirths (n=1554), 
terminations of pregnancy (n=787) and severe congenital anom-
alies (n=123). Infants with severe congenital anomalies were 
excluded because of differences in screening and termination poli-
cies across the regions22 and consequent effects on mortality and 
morbidity. For the analysis of morbidity, our primary study popu-
lation was infants discharged home or into long-term institutional 
care (n=6422). We also computed morbidity rates among neonatal 
admissions and inhospital deaths to allow comparison with other 
studies and to assess selection into our sample.
Definition of outcomes
Severe neonatal morbidity was defined as a composite measure of 
cystic periventricular leukomalacia (cPVL), intraventricular haem-
orrhage (IVH grades III and IV), surgical necrotizing enteroco-
litis (NEC requiring surgical treatment or peritoneal drainage) or 
retinopathy of prematurity (ROP≥stage 3). Severe BPD was need 
for oxygen with the fraction of inspired oxygen (FiO2) >30% or 
need for respiratory support (mechanical ventilation and non-in-
vasive ventilation) at 36 weeks of postmenstrual age among survi-
vors to ≥36 weeks.23 As data on FiO2 were not collected in two 
regions in the UK, we chose not to include severe BPD in our 
primary composite, but analysed it separately. Inhospital mortality 
was death after live birth before discharge from neonatal care, 
including labour ward deaths.
Covariables
Maternal, pregnancy and neonatal characteristics used to adjust 
for population differences are those that differ between regions, 
have an impact on mortality and morbidity and do not reflect 
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Table 3 Associations between infant and pregnancy characteristics 
and severe morbidity: infants discharged from neonatal 
hospitalisation (n=6422)
Characteristics n % P Adjusted rr (95% CI)
Infant characteristics
Gestational age
  23 19 61.3 <0.001 45.55 (32.02 to 64.80)
  24 103 51.8 22.26 (14.51 to 34.15)
  25 99 34.5 19.33 (13.91 to 26.86)
  26 104 23.4 13.65 (9.75 to 19.11)
  27 90 15.3 8.70 (6.19 to 12.24)
  28 77 10.0 5.55 (3.91 to 7.89)
  29 58 6.4 3.82 (2.66 to 5.49)
  30 69 5.3 2.30 (1.56 to3.40)
  31 44 2.6 Ref
Sex
  Male 296 10.3 0.365 Ref
  Female 367 11.0 1.10 (0.96 to 1.27)
Type of pregnancy
  Singleton 483 11.3 0.012 Ref
  Multiple 180 9.2 0.94 (0.79 to 1.12)
SGA*
  <10th 183 9.1 0.008 0.82 (0.68 to 0.98)
  ≥10th 480 11.4 Ref
Maternal and pregnancy characteristics
Maternal age
  <35 years 497 10.9 0.200 Ref
  35 years 161 9.8 1.01 (0.86 to 1.18)
Parity
  Nulliparous 381 10.8 0.459 Ref
  Multiparous 274 10.3 0.94 (0.81 to1.08)
PPROM 164 10.8 0.815 0.92 (0.78 to1.08)
Pre-eclampsia/
eclampsia/HELLP
70 7.2 <0.001 0.76 (0.59 to 0.98)
Congenital anomaly† 67 14.5 0.005 1.34 (1.07 to 1.67)
*Small for gestational age, using intrauterine references. 
†Congenital anomalies reportable to Eurocat, but not severe. Cases with severe 
anomalies were excluded.
HELLP, hemolysis elevated liver enzymes low platelet count; PPROM, preterm 
premature rupture of membrane; RR, relative risk. 
obstetrical or neonatal care.9 These include maternal age; parity; 
multifetal pregnancy; pregnancy complications (pre-eclampsia, 
eclampsia/hemolysis elevated liver enzymes low platelet count), 
preterm premature rupture of membranes >12 hours; GA in 
completed weeks; small for gestational age (SGA) defined as 
a birth weight for GA≤10th percentile of intrauterine growth 
curves24; infant sex and presence of congenital anomalies. 
Congenital anomalies were those reportable to Eurocat,25 but 
not considered severe,9 as these were excluded. We also describe 
other perinatal care and health outcomes: delivery in a level 
III maternity unit using national definitions (yes/no), antenatal 
corticosteroids administration (any/no), mode of delivery (prela-
bour caesarean, intrapartum caesarean or vaginal delivery), 5 min 
Apgar score, initial respiratory support (none, nasal continuous 
positive airway pressure (nCPAP) or mechanical ventilation) and 
neonatal transport within 48 hours after birth.
statistical analyses
We first described the prevalence of severe neonatal morbidity 
without and with severe BPD by region for surviving infants<32 
weeks of GA and by GA subgroup (<28 weeks and 28–31 weeks 
of GA). Descriptive tables were also generated for neonatal 
admissions and inhospital deaths.
We then computed adjusted rates of mortality and severe 
neonatal morbidity (without and with severe BPD) taking into 
consideration maternal, pregnancy and infant characteristics. 
Adjusted rates were derived using logistic regressions following 
methods used to analyse mortality in the EPICE sample.9 For 
each region, the ratio of the observed to the expected number of 
events was calculated by using the estimated predicted probabil-
ities and was then multiplied by the observed rate in the study 
population. We used the Wald test to assess the significance 
of region in unadjusted and adjusted models. The variation 
between regions was quantified through the SD of the mortality 
percentages for the regions, expressed as a coefficient of vari-
ation. To test associations between adjusted regional mortality 
and morbidity rates, we used Spearman rank correlations. We 
used a minimal adjustment model for each individual morbidity 
component, including only GA, because of the low number of 
cases.
ethics
Ethical approval and informed parental consent (active or 
passive, depending on each participating country’s national 
legislation) for data collection were obtained in each study 
region. In the French regions, EPICE was carried out as part of 
the EPIPAGE 2 study, and parents had to consent to all parts of 
data collection, leading to 6.4% of total births for which consent 
could not be obtained.
resuLTs
The mean GA was 28.4 weeks and mean birth weight was 1194 g 
(table 1); 31.5% were <10th percentile by intrauterine growth 
standards, while 31.2% were multiples; 86.3% received ante-
natal corticosteroids and 64.8% were born by caesarean section. 
Over one quarter of the sample had mothers 35 years of age 
or over and 56.2% had primparous mothers. The inhospital 
mortality rate was 13.6% for all infants<32 weeks, 33.5% for 
infants<28 weeks and 4.2% for infants 28 to 31 weeks.
severe morbidity rates by GA groups
Overall, 10.6% of survivors had one or more severe neonatal 
morbidities without severe BPD and 13.8% had severe morbidity 
when severe BPD was included (table 2A). Severe NEC was the 
least prevalent of the morbidities (1.9%), followed by cPVL 
(3.2%), ROP≥stage3 (3.7%), IVH grades III and IV (3.9%) and 
severe BPD (5.5%). For morbidity without BPD, the regional 
range was from <8% in Ile-de-France, the Northern region 
in France and Sweden (greater Stockholm area), to 23.5% in 
Poland (Wielkopolska).
For infants born before 28 weeks of GA, severe neonatal 
morbidity rates without and with severe BPD were 26.8%, and 
36.9%, respectively (table 2B). Severe BPD, ROP≥stage 3 and 
IVH grade III/IV were the most prevalent morbidities. Vari-
ation between regions was wide (16% to >40%) for the 
composite variables. For infants 28 to 31 weeks, morbidity 
rates were 5.3% without severe BPD and 7.0% with severe 
BPD (table 2C); IVH grades III and IV, cPVL and severe BPD 
were the most prevalent morbidities. Differences between 
regions were significant (P<0.001) across both subpopulations 
and composite indicators.
The overall morbidity rate was higher when calculated for 
neonatal admissions (online supplementary table S1). Among 
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Figure 1 Association between adjusted severe neonatal morbidity composite, excluding severe bronchopulmonary dysplasia among survivors, and 
adjusted mortality rates in 16 European regions.
deaths, 28% had a diagnosis of at least one morbidity, principally 
IVH grade III/V (22.1%) and NEC (6.5%). Proportions were 
lower for other morbidities with later age at diagnosis (online 
supplementary table S2).
Adjustment for maternal and neonatal characteristics
While several maternal and neonatal characteristics were asso-
ciated with severe neonatal morbidity in univariable analyses, 
only GA, SGA, pre-eclampsia/eclampsia and congenital anom-
alies remained significant in multivariable analyses, as shown 
in table 3. This was the model used to compute the adjusted 
morbidity rates. Regional variation remained significant after 
adjustment (P<0.001). The coefficient of variation of regional 
rates decreased from 35.2% to 31.7% after adjustment (59.9% 
to 51.8% for infants 28–31 weeks and 28.5% to 27.4% for 
infants <28 weeks).
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Table 4 Spearman’s correlations between adjusted very preterm 
mortality and rates of individual morbidities, adjusted for GA, in 16 
European regions, all births <32 weeks of GA and by GA subgroups
<28 weeks' GA 28–31 weeks' GA Total <32 weeks' GA
rho P value rho P value rho P value
IVH grade III/IV 0.38 0.15 0.43 0.10 0.69 <0.01
cPVL 0.02 0.93 0.30 0.26 0.22 0.42
ROP stage 3+ 0.08 0.75 −0.01 0.98 0.14 0.61
Severe NEC −0.45 0.08 0.26 0.33 −0.27 0.31
Severe BPD 0.11 0.71 −0.47 0.09 −0.11 0.70
BPD, bronchopulmonary dysplasia; cPVL, cystic periventricular leukomalacia; 
GA, gestational age; IVH, intraventricular haemorrhage; NEC, necrotizing 
enterocolitis; ROP, retinopathy of prematurity. 
Association between regional rates of morbidity and 
mortality
Risk-adjusted regional mortality rates ranged from 8.4% 
to 18.8% (unadjusted 7.3% to 21.1%) for the overall 
sample, 19.4% to 45.4% (unadjusted 17.0% to 43.8%) for 
infants <28 weeks and 1.4% to 6.0% (unadjusted 1.5% to 
7.5%) for those 28–31 weeks (online supplementary table 
S3). Figure 1 illustrates the absence of an association between 
in-hospital mortality and morbidity without BPD among 
survivors, as shown by the Spearman rho included with the 
figure. Spearman rank correlations for each individual severe 
morbidity did not reveal negative associations, but there was 
a positive association with severe IVH (table 4). Scatter plots 
for each morbidity are included in supplementary material 
(online supplementary figure S1–S3)
DIsCussIOn
Our study reveals wide variability in severe neonatal morbidity 
rates for very preterm infants across European regions: from 
6% to 24% for overall morbidity without severe BPD. We did 
not observe a trade-off between rates of mortality and severe 
neonatal morbidity among surviving infants. In fact, for indi-
vidual morbidities, we observed higher rates of severe brain 
lesions in higher mortality regions. Adjustment for maternal and 
neonatal characteristics reduced the variation between regions, 
but regional differences remained significant.
strengths and limitations
The strengths of our study are its population-based design and 
the use of a common and pretested protocol for medical record 
abstraction. The morbidities included in this study have well-es-
tablished definitions. For BPD, we used the fraction of inspired 
oxygen at 36 weeks or respiratory support to define severe 
cases.23 Two regions did not collect information on FiO2 and 
thus we could not include severe BPD in our primary outcome 
variable. However, results associating morbidity with mortality 
were similar without and with severe BPD, although rates of 
severe neonatal morbidity increased from 10.6% to 13.8% 
with the latter. Our regional samples were not large enough to 
provide a high degree of precision for the prevalence of indi-
vidual morbidities; variability due to random chance should 
be considered when comparing the results between regions. 
Finally, we did not have data on maternal socioeconomic status. 
However, while socioeconomic factors are major predictors 
of preterm birth risk and the health and development of very 
preterm children26 27 they have not been associated with inhos-
pital mortality or morbidity.28 29
Comparison with other studies
Comparison of morbidity rates across studies is complicated 
because of the use of different definitions, GA cut-offs and popu-
lation inclusion criteria. The US Neonatal Research Network 
centres reported rates of IVH grade III/IV of 15%, cPVL 4%, 
NEC (Bell stage 2–3) 10% and ROP, stage 3 or more, 12% 
among infants born at less than 28 weeks in 2008–2012 and 
surviving more than 12 hours after birth.13 A California popula-
tion-based study of survivors born at 22–28 weeks using hospital 
data reported rates of 7.5% for IVH grade III/IV, 2.3% for PVL, 
6.7 for NEC and 9.9% for ROP requiring surgery.30 Among 
survivors born at 28–31 weeks in the EPIPAGE 2 cohort in 
France in 2011,14 the rate of IVH grade III or more was 3.1%; 
cPVL 1.6%; ROP stage 3 or more 0.1%. Among survivors born 
at 28–31 weeks, severe BPD was 3.1% and NEC 3.2%. These 
results are within ranges in our study; some differences are due 
to use of neonatal intensive care unit admissions versus survi-
vors, which leads to increased rates. Our results are also in line 
with recent findings from studies over time concluding that there 
is no obvious trade-off between mortality and severe morbidity 
rates among survivors.6 13
Interpretation
Differences in regional morbidity rates were attenuated, but 
persisted, after risk adjustment. Fewer maternal and neonatal 
characteristics were associated with morbidity compared with 
previous analyses of mortality.9 As risk factors differ for indi-
vidual morbidities, adjustment for patient case mix may be 
more complex when morbidity is analysed as a composite. For 
instance, SGA is not a risk factor for IVH or PVL, but strongly 
affects BPD31; male sex is strongly related to IVH, but may be 
less important for other morbidities.32
In previous studies, regional differences have been 
attributed to variations in the use of interventions, such 
as tocolytics, administration of antenatal corticosteroids, 
delivery in tertiary centres and respiratory care.4 In this 
cohort, admission hypothermia varied widely between 
different regions and was associated with an almost twofold 
risk of neonatal mortality.33 However, there was no associ-
ation with morbidity.33 Other evidence-based interventions 
in this cohort also showed a larger impact on mortality than 
morbidity.21 At the lowest GAs (22–24 weeks), initiation of 
active care may also differ between regions and influence the 
risks of mortality and neonatal morbidity.34 35
Implications for practice and policy
The variation in severe neonatal morbidity rates across 
regions suggests that reductions are possible with current 
medical knowledge. Very preterm birth leads to high costs for 
families, health services and societies due to life-long neuro-
developmental and other impairments.36 It is also associated 
with worse long-term health-related quality of life.37 Given 
the strong association between severe neonatal morbidity and 
adverse longer-term outcomes38 effective preventive actions 
represent a cost-effective use of finite healthcare resources. 
This focus is particularly important as the active management 
of extremely preterm infants becomes more widespread.35 
Furthermore, we show the importance of having compa-
rable international indicators of severe neonatal morbidity 
for surveillance, benchmarking and the large-scale research 
studies needed to improve our understanding of the determi-
nants of severe neonatal morbidity.
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